转移性结直肠癌治疗前[18F]FDG PET/CT影像组学分析
本研究评估转移性结直肠癌患者一线或三线姑息系统治疗前[18F]FDG PET影像组学特征与疗效及生存的关联。三线治疗组病灶SUVmax、SUVpeak、SUVmean、MATV、TLG较高,AUC-CSH、致密度、球形度较低,故两组分别分析。一线组无获益者平均熵较高(p=0.021);一线和三线组中平均AUC-CSH降低及MATV、TLG升高均与无进展生存和总生存较差相关。
要点
- 一线组无获益者平均熵较高(p=0.021)
- 一线组平均AUC-CSH降低与PFS、OS较差相关(HR 0.86、0.77)
- 三线组平均MATV、TLG升高与PFS、OS较差相关
核心结论
- 治疗前[18F]FDG PET显示肿瘤体积小、异质性低及球形度高与临床结局较好相关
- 未来PET影像研究在将PET数据与临床结局关联时应纳入包含肿瘤体积和异质性的影像组学特征
研究设计与样本
- 转移性结直肠癌患者在一线或三线姑息系统治疗前接受[18F]FDG PET/CT检查
- 对肿瘤病灶进行半自动勾画,获取SUV、代谢活跃肿瘤体积(MATV)、总病灶糖酵解(TLG)、熵、累积SUV-体积直方图曲线下面积(AUC-CSH)、致密度和球形度等影像组学特征
- 接受三线系统治疗的47例患者病灶与接受一线系统治疗的52例患者分别评估
主要发现
- 三线组47例病灶SUVmax、SUVpeak、SUVmean、MATV和TLG高于一线组52例,AUC-CSH、致密度和球形度低于一线组
- 一线组CT解剖学变化与TLG(ρ=0.31)和MATV(ρ=0.36)负相关,与致密度(ρ=-0.27)和球形度(ρ=-0.27)正相关
- 一线组无获益者平均熵较高(p=0.021)
- 一线组平均AUC-CSH降低与PFS(HR 0.86)和OS(HR 0.77)较差相关,平均MATV升高与PFS(HR 1.15)和OS(HR 1.22)较差相关,sum MATV升高与PFS(HR 1.14)和OS(HR 1.19)较差相关,平均TLG升高与PFS(HR 1.16)和OS(HR 1.22)较差相关,sum TLG升高与PFS(HR 1.12)和OS(HR 1.18)较差相关
- 三线组AUC-CSH与解剖学变化负相关(ρ=0.21),平均MATV升高与PFS(HR 1.27)和OS(HR 1.68)较差相关,sum MATV升高与PFS(HR 1.35)和OS(HR 2.04)较差相关,平均TLG升高与PFS(HR 1.29)和OS(HR 1.52)较差相关,sum TLG升高与PFS(HR 1.27)和OS(HR 1.80)较差相关,SUVmax与OS负相关(HR 1.19),SUVpeak与OS负相关(HR 1.21)
关键数值与推荐
- 一线组无获益者平均熵较高(p=0.021)
- 一线组平均AUC-CSH降低与PFS较差相关(HR 0.86),与OS较差相关(HR 0.77)
- 一线组平均MATV升高与PFS较差相关(HR 1.15),与OS较差相关(HR 1.22)
- 三线组平均MATV升高与PFS较差相关(HR 1.27),与OS较差相关(HR 1.68)
- 三线组sum MATV升高与PFS较差相关(HR 1.35),与OS较差相关(HR 2.04)
临床怎么用
- 原文未据此给出推荐
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The aim of this study was to assess radiomics features on pre-treatment [18F]FDG positron emission tomography (PET) as potential biomarkers for response and survival in patients with metastatic colorectal cancer (mCRC). METHODS: Patients with mCRC underwent [18F]FDG PET/computed tomography (CT) prior to first- or third-line palliative systemic treatment. Tumour lesions were semiautomatically delineated and standard uptake value (SUV), metabolically active tumour volume (MATV), total lesion glycolysis (TLG), entropy, area under the curve of the cumulative SUV-volume histogram (AUC-CSH), compactness and sphericity were obtained. RESULTS: Lesions of 47 patients receiving third-line systemic treatment had higher SUVmax, SUVpeak, SUVmean, MATV and TLG, and lower AUC-CSH, compactness and sphericity compared to 52 patients receiving first-line systemic treatment. Therefore, first- and third-line groups were evaluated separately. In the first-line group, anatomical changes on CT correlated negatively with TLG (ρ = 0.31) and MATV (ρ = 0.36), and positively with compactness (ρ = -0.27) and sphericity (ρ = -0.27). Patients without benefit had higher mean entropy (p = 0.021). Progression-free survival (PFS) and overall survival (OS) were worse with a decreased mean AUC [hazard ratio (HR) 0.86, HR 0.77] and increase in mean MATV (HR 1.15, HR 1.22), sum MATV (HR 1.14, HR 1.19), mean TLG (HR 1.16, HR 1.22) and sum TLG (HT1.12, HR1.18). In the third-line group, AUC-CSH correlated negatively with anatomical change (ρ = 0.21). PFS and OS were worse with an increased mean MATV (HR 1.27, HR 1.68), sum MATV (HR 1.35, HR 2.04), mean TLG (HR 1.29, HR 1.52) and sum TLG (HT 1.27, HR 1.80). SUVmax and SUVpeak negatively correlated with OS (HR 1.19, HR 1.21). Cluster analysis of the 10 radiomics features demonstrated no complementary value in identifying aggressively growing lesions or patients with impaired survival. CONCLUSION: We demonstrated an association between improved clinical outcome and pre-treatment low tumour volume and heterogeneity as well as high sphericity on [18F]FDG PET. Future PET imaging research should include radiomics features that incorporate tumour volume and heterogeneity when correlating PET data with clinical outcome.
引用
- van Helden EJ, Vacher YJL, van Wieringen WN, et al. Radiomics analysis of pre-treatment [18F]FDG PET/CT for patients with metastatic colorectal cancer undergoing palliative systemic treatment. Eur J Nucl Med Mol Imaging. 2018. PMID: 30094460. doi:10.1007/s00259-018-4100-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。